CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
MDA2016-08-02 CP-CTNet_CLO-MD Anderson A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer Cancer Prevention and Control CIRB
MDA2017-09-03 CP-CTNet_CLO-MD Anderson Pilot Study of Denosumab in BRCA1/2 Mutation Carriers scheduled for Risk-reducing Salpingooophorectomy Cancer Prevention and Control CIRB
MDA21-06-01 CP-CTNet_CLO-MD Anderson A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome Cancer Prevention and Control CIRB
MM1MDS-A01 Alliance A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study Adult CIRB - Late Phase Emphasis
MM1OA-EA02 ECOG-ACRIN A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial Adult CIRB - Late Phase Emphasis
MM1OA-S03 SWOG Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy Adult CIRB - Late Phase Emphasis
MM1YA-S01 SWOG A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by myeloMATCH; A myeloMATCH Clinical Trial Adult CIRB - Late Phase Emphasis
MyeloMATCH SWOG Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials Adult CIRB - Late Phase Emphasis
N0147 NCCTG A Randomized Phase III Trial of Oxaliplatin (OXAL) plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer Adult CIRB - Late Phase Emphasis
N0434 (MA.27D) NCCTG The Association of Breast Density Changes; Plasma Hormone Changes; and<br>Breast Cancer Recurrence: A Companion Study to NCIC CTG MA.27 Adult CIRB - Late Phase Emphasis